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Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) are
remarkably effective inducing deep molecular remission in most patients. However, they are less
effective to eradicate the leukemic stem cells (LSC), resulting in disease persistence. Therefore, there is
great need to develop novel therapeutic strategies to specifically target the LSC. In an experimental
mouse CML model system, the leukotriene pathway, and specifically, the expression ALOX5, encoding 5-
lipoxygenase (5-LO), has been reported as a critical regulator of the LSC. Based on these results, the 5-LO
inhibitor zileuton has been introduced in clinical trials as a therapeutic option to target the LSC although
its effect on primary human CML LSC has not been studied. We have here by using multiplex single cell
PCR analyzed the expression of the mediators of the leukotriene pathway in bone marrow (BM) BCR-
ABLþCD34þCD38 cells at diagnosis, and found low or undetectable expression of ALOX5. In line with
this, zileuton did not exert significant overall growth inhibition in the long-term culture-initiating cell
(LTC-IC) and colony (CFU-C) assays of BM CD34þCD38 cells from 7 CML patients. The majority of the
single leukemic BCR-ABLþCD34þCD38 cells expressed cysteinyl leukotriene receptors CYSLT1 and
CYSLT2. However, montelukast, an inhibitor of CYSLT1, also failed to significantly suppress CFU-C and LTC-
IC growth. These findings indicate that targeting ALOX5 or CYSLT1 signaling with leukotriene antago-
nists, introduced into the clinical practice primarily as prophylaxis and treatment for asthma, may not be
a promising pharmacological strategy to eradicate persisting LSC in CML patients.
© 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chronic myeloid leukemia (CML) is characterized by the
expression of the BCR-ABL fusion protein, a constitutively active
tyrosine kinase that promotes growth of leukemic stem and pro-
genitor cells by multiple signaling pathways involved in cell sur-
vival, proliferation and differentiation [1]. The leukemic stem cellsier Inc. This is an open access artic(LSC) in chronic phase CML reside in a phenotypically similar stem
and progenitor cell population (CD34þCD38) as normal bone
marrow (BM) stem and progenitor cells [1,2] and differentiate
predominantly into an expanding population of granulocytes,
thrombocytes and their precursors, whereas in the terminal phase,
blast crisis, immature lymphoid or myeloid progenitors accumulate
as leukemic blasts.
Tyrosine kinase inhibitors (TKI) including imatinib, targeting the
BCR-ABL oncoprotein, have been remarkably effective in inducing
deep molecular remission in most CML patients. However, TKI arele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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most often necessitating lifelong pharmacological therapy and
carrying a risk for development of drug resistance and progression
to blast crisis [3]. Therefore, there is a great need to identify addi-
tional therapeutic strategies to specifically target LSC in CML.
Leukotrienes (LT) are biologically active lipidmediators involved
in inflammatory processes and in malignant diseases [4,5]. The first
step in LT biosynthesis is conversion of arachidonic acid by 5-
lipoxygenase (5-LO). In an experimental mouse CML model, the
gene encoding 5-LO, ALOX5 was overexpressed in stem cells
transfected with BCR-ABL [6], and loss of ALOX5 in the BCR-ABLþ
LSC impaired the development of leukemia. Treatment with
zileuton, an inhibitor of 5-LO, specifically inhibited the develop-
ment of leukemia but did not inhibit the non-leukemic stem cells in
this mouse model [6]. Based on these results, zileuton was pro-
posed to be an option to eradicate the human LSC and to offer
potential to improve the treatment of CML [7]. However, low levels
of ALOX5 transcript were found at diagnosis in CD34þ progenitors
of patients with chronic phase CML as compared to normal CD34þ
progenitors [8]. Its expression and function in the more primitive
leukemic BCR-ABLþ CD34þCD38 cells of CML patients has not been
explored.
During LT biosynthesis from arachidonic acid, LTA4, an unstable
intermediate product, is converted by LTA4 hydrolase (LTA4H) to
LTB4 or by LTC4 synthase (LTC4S) to cysteinyl-containing LTC4,
which is further metabolized to cysteinyl LTD4 and LTE4. The
expression and activity of LTC4S has been shown to be increased in
myeloid cells in patients with CML [9,10]. While LTB4 binds to re-
ceptors BLT1 and BLT2, the cysteinyl LT act on target cells mainly
through the G-protein coupled receptors CYSLT1 and CYSLT2 [5].
Recently, the expression of the CYSLT receptors in CML cell lines
was reported [11], and montelukast, an inhibitor of CYSLT1, was
found to suppress in vitro growth of CML blast crisis cell lines [11].
So far, the effects of montelukast and zileuton on the primary
CD34þCD38 stem and progenitor cells from patients with CML
have not been reported, even though zileuton, combined with TKI
has already been introduced into clinical trials in CML (clinicaltrials.
com, NCT02047149, NCT01130688) with as yet no available efficacy
data.
To assess the expression and function of LT signaling molecules
in leukemic CD34þCD38 BM cells we have here employed multi-
plex single cell PCR and in vitro stem and progenitor cell assays
using the LT inhibitors zileuton and montelukast, and cells from
newly diagnosed CML patients. We found a low frequency of
ALOX5-expressing CD34þCD38 cells in the CML patient samples,
and no significant overall growth suppression of BM CD34þCD38
cells from CML patients by zileuton in the long-term culture-initi-
ating cell (LTC-IC) and colony (CFU-C) assays. Although themajority
of the leukemic BCR-ABLþCD34þCD38 cells expressed CYSLT1 and
CYSLT2 receptors, montelukast failed to significantly inhibit growth
of CML BM CD34þCD38 cells. These data suggest that targeting
ALOX5 or CYSLT1 signaling with leukotriene signaling antagonists
may not be a promising pharmacological strategy to eradicate CML
LSC in patients in the clinic.
2. Materials and methods
2.1. Human sample collection and CD34þCD38 cell sorting by FACS
BM aspirates collected from healthy adult volunteers and newly
diagnosed patients with chronic phase CML (n ¼ 10, Table S1) were
used in accordance with approved protocols (LU-195-00, LU-826-
2004, 2012/4:10 and 2013/3:1). The WHO criteria for chronic
phase CMLwere employed [12]. Mononuclear cells were isolated by
Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS, Oslo, Norway).The CD34þ cells were enriched by using CD34 MicroBead Kit
(Miltenyi Biotech, Bergisch Gladbach, Germany). The CD34þ or
CD34þCD38 cells were further sorted by FACSAriaIII Cell Sorter
(BD Biosciences) after staining with monoclonal antibodies (BD
Biosciences, San Jose, CA, USA), anti-CD34-FITC or APC (8G12) and
anti-CD38-PECY7 or PE (HB7). The gates were set according to
fluorescence-minus-one controls. The dead cells were excluded by
propidium iodide (PI; Invitrogen) staining.
2.2. Reagents
Imatinib and leukotriene antagonists were provided by Cayman
Chemical Company (Ann Arbor, MI, USA). Stock solutions were
prepared with DMSO (imatinib 10 mM, montelukast 50 mM and
zileuton 100 mM). The final concentrations used in cultures were
imatinib 1 or 5 mM, and zileuton and montelukast 20 mM.
2.3. Colony assays
The purified CD34þCD38 or CD34þ cells were cultured at a
density of 150 cells/dish (for CD34þ cells) or 50 cells/dish (for
CD34þCD38 cells) in Methocult H4435 (Stem Cell Technologies) in
duplicate. The colony-forming units in culture (CFU-Cs) were
counted at day 14.
2.4. LTC-IC assay
LTC-IC assay was performed as described [13,14]. The
CD34þCD38 cells were sorted directly and plated in 200 mL Mye-
locult H5100 (Stem Cell Technologies), 106 M hydrocortisone
(Sigma) in Collagen I coated or plain 96-well microplates (BD Bio-
sciences) on irradiated (8000 cGy) murine stromal cell line M2-
10B4 (10000 cells/well), engineered to express human cytokines,
IL-3 and G-CSF [13]. The cells were seeded at 3, 10, 30 and 100 cells/
well or 1, 3, 10 and 30 cells/well, 10e18 replicates except for 30 or
100 cells/well where a small total cell number in some cases
restricted the number of replicates. Imatinib and/or leukotriene
antagonists or DMSO in the corresponding final concentration as in
the inhibitors, were added at the initiation of the cultures, and the
cultures were maintained at 37 C and 5% CO2 for 6 weeks with
weekly half-medium change. Thereafter 140 mL of the mediumwas
carefully removed and the wells were overlaid with 150 mL
Methocult H4435/well. The wells were scored as positive or
negative after 14 days, and the frequencies of LTC-IC were calcu-
lated using the L-Calc software (StemCell Technologies).
2.5. Multiplex single-cell RT-PCR analysis
Single-cell RT-PCR analysis was performed as previously
described [15]. The CD34þCD38 CML cells were deposited directly
at 1 cell/well in 4 mL of lysis buffer (dNTPs, DTT, 10% NP40, RNase
inhibitor) per well in 96-well plates (Thermo Scientific, #AB-0800).
Cell lysates were reverse transcribed using multiple pairs of gene-
specific reverse primers and 50U MMLV-RT per reaction in the
buffer provided by the supplier (200 U/ml, Life technologies). The
first-round PCR with 35 cycles was performed by addition of 40 ml
PCR buffer and 1.25 U Taq polymerase (TaKaRa kit, Clonetech). One
microliter aliquots of first-round PCRs were further amplified using
fully nested gene-specific primers. Aliquots of second-round PCR
products were subjected to gel electrophoresis and visualized by
GelRed™ staining (Invitrogen) on 1.5e3% agarose gel. The expres-
sion of BCR/ABL and the leukotriene pathway genes (CYSLTR1,
CYSLTR2, ALOX5, and LTA4H) were analyzed simultaneously with
HPRT, a reference gene. The wells were defined as positive for
containing one cell if they were positive for HPRT gene product, or
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negative for HPRT. The primer sequences are listed in Table S2.2.6. Statistics
Statistical differences were evaluated by Wilcoxon matched-
pairs signed rank test. The two-sided p-value was considered to
be significant when p < 0.05.
See supplemental materials for additional methods.3. Results
3.1. Expression of LT signaling molecules in single CML
CD34þCD38BCR-ABLþ cells
To specifically analyze the expression of LT signaling molecules
in LSC, we determined the co-expression of BCR-ABL with LT
pathway mediators ALOX5, CYSLTR1, CYSLTR2 and LTA4H mRNA in
single BM CD34þCD38 cells from 8 CML patients (Table S1) by
using nested RT-PCR (Fig. 1). The frequencies of the BCR-ABLþ cells
were 38%e70% of the CD34þCD38 cells (Figs. 1C and 2A). Notably,
ALOX5was undetectable in one BM sample and was expressed only
in a small fraction of leukemic BCR-ABLþCD34þCD38 cells in most
BM samples with a median frequency of 10.6% (Fig. 2). The median
frequency of residual nonleukemic BCR-ABL- cells expressing ALOX5
was similarly low (16.0%). The expression of LTA4Hwas overall high
with median frequencies of 95.6% and 79.6% in the BCR-ABLþ and
BCR-ABL- cells, respectively (Fig. 2B). The cysteinyl LT receptors
CYSLTR1 and CYSLTR2 were also expressed in most BCR-ABLþ LSC
(median frequency of 64.5% and 57,3%, respectively) and BCR-ABL-
CD34þCD38 cells (median frequency of 71.7% and 81.7%, respec-
tively) (Fig. 2B).Fig. 1. Multiplex single cell RT-PCR analysis showing expression of leukotriene signalin
(A) Experimental setup for nested-PCR and in vitro function inhibition assays of CML stem an
analysis and for LTC-IC assay. For single cell PCR, the cells were deposited directly in 96-well
nested PCR to amplify the genes. The electrophoresis was run to identify the specific RT-PC
(B) FACS profile for sorting of CML CD34þCD38 cells. The cells were gated for live PI CD3
(C) The frequencies of BCR-ABLþ cells within the CD34þCD38 cells in the CML patients de
(D) Representative image of RT-PCR products for CYSLTR1, CYSLTR2, ALOX5, LTAH4 and HPRT3.2. Growth response of CML CD34þCD38BCR-ABLþ cells to
imatinib and LT signaling inhibitors in LTC-IC assay
To test the functional response of the primitive leukemic stem
and progenitor cells to the LT inhibitors zileuton or montelukast
alone and in combination with imatinib, we performed limiting
dilution LTC-IC assay of BM CD34þCD38 cells from 7 CML patients
and 5 healthy donors (Fig. 3). The median frequencies of LTC-IC in
BM CD34þCD38 cells from CML patients and normal BM donors
were 0.38 and 0.40, respectively, in agreement with a previous
report [17]. Imatinib induced a reduction of LTC-IC frequencies in
CD34þCD38 cells from 6 out of 7 tested CML patient samples,
representing a significant overall growth inhibition (median of 0.12,
p ¼ 0.03) (Fig. 3A, C). In contrast to imatinib, neither zileuton nor
montelukast were able to induce significant overall inhibition of
LTC-IC growth of the 7 tested CML BM samples (Fig. 3A), although
some reductions were observed in CML5 by 38.2% and in CML8 by
53% compared to the DMSO control. Similarly, no significant addi-
tive inhibition could be detected when the LT inhibitors were
combined with imatinib (Fig. 3A,C). However, in a BM sample
(CML8) from a patient who progressed to blast crisis soon after
diagnosis (Table S1), zileuton in combinationwith imatinib seemed
to further suppress LTC-IC activity of the CD34þCD38 cells with
the LTC-IC frequency reduced from 0.031 in zileuton alone to 0.018
in zileuton plus imatinib (Fig. 3A). Cytopenias are known off-target
effects of imatinib, and inhibition of LTC-IC activity by imatinib was
seen in some healthy donor BM CD34þCD38 cells. Although some
inhibition by zileuton and montelukast, comparable to that
observed in few CML samples, was seen in the LTC-IC assays of few
normal BM samples, there was no significant overall decrease in
LTC-IC frequencies in the normal BM in cultures with imatinib, LT
inhibitors or the combination (Fig. 3B,D).g molecules in BCR-ABLþ and BCR-ABL-CD34þCD38¡ cells of CML patients.
d progenitor cells to LT inhibitors. The CD34þCD38 cells were sorted for single cell PCR
plates at 1 cell/well and subjected to cDNA synthesis followed by two-round multiplex
R products.
4þ cells and subsequently gated for CD34þCD38 cells.
tected by single cell PCR.
.
Fig. 2. Expression pattern of leukotriene signaling molecules in single CD34þCD38¡ cells from 8 newly diagnosed CML patients.
(A) Color-coated maps show co-expression pattern of BCR-ABL, HPRT, LTAH4, CYSLTR1, CYSLTR2 and ALOX5 mRNA in single CD34þCD38 cells from CML patients. HPRT was used a
reference gene. The color-coated squares indicate that an RT-PCR product for the indicated genes could be detected on GelRed-stained agarose gel. Each row represents a single cell.
The numbers at bottom of the panel indicate the number of cells expressing the indicated gene and total number of the cells analyzed. The cells from patient 2 were isolated from
blood.
(B) ALOX5, CYSLTR1, CYSLTR2 and LTA4H, expression within the leukemic BCR-ABLþ and non-leukemic BCR-ABL- CD34þCD38 BM cells from 7 patients and blood cells from 1 patient
(patient 2) with CML.
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by zileuton or montelukast
CFU-C assays were performed on CD34þ cells from 5 CML pa-
tients (Fig. 3E). Not surprisingly, total CFU-Cs were dramatically
suppressed by imatinib in all 9 assays of 6 patient samples
(p ¼ 0.03), in agreement with the reported more efficient sup-
pression by imatinib of less primitive leukemic progenitor cells
[18]. Inhibition of CFU-C growth by imatinib was similar at 1 mM
and 5 mM (Fig. S1). There was no significant inhibition in the colony
growth by montelukast or zileuton.
3.4. Residual BCR-ABLþ cells were detected in single colonies from
LTC-IC cultures
In order to determine whether the LT inhibitors could specif-
ically target the LSC in the LTC-IC cultures, we analyzed cells from
these cultures by FISH for the BCR-ABL fusion gene.We could detect
residual BCR-ABLþ cells after all treatments (Fig. 4), showing that
even when total LTC-IC frequencies were reduced by imatinib
(Patients CML3, 7, and 9, Fig. 3), LSCs were not fully eradicated.
4. Discussion
Signaling pathways mediated by leukotrienes have been iden-
tified as important regulators of acute and chronic inflammation,
but are also involved in the pathogenesis in several types of cancers,
including colon, lung, prostate and breast cancers. In line with this,
studies using in vivo murine colon cancer xenograft models havedemonstrated notable potential of both zileuton and montelukast
as anti-cancer agents, suggesting that inhibiting LT signaling may
be a promising additional pharmacological strategy to target these
tumors [19].
The role of LT signaling in human normal hematopoiesis and
leukemia remains elusive. The receptor for LTB4, BLT1 is expressed
in CD34þ cells in CML at diagnosis and its expression appeared to
be correlated with the clinical response to imatinib [8]. In addition,
the other LTB4 receptor BLT2 was found to be upregulated by BCR-
ABL in primary CML blast crisis CD34þ progenitors, and inhibition
of this receptor suppressed proliferation and induced apoptosis of
the leukemic cells [20]. High expression of CYSLTR1was reported in
chronic lymphocytic leukemia, and in vitro inhibition of it induced
apoptosis of the leukemic cells, suggesting this receptor as a po-
tential therapeutic target [21].
Based on these reports suggesting a role for 5LO/ALOX5 and/or
cysteinyl LT signaling in solid cancers and in leukemia, we have
here focused on the expression of the target molecules of these two
respective inhibitors zileuton and montelukast in primary BCR-
ABLþ CD34þCD38 LSC from CML patient at diagnosis and their
in vitro functional response to these inhibitors. We show by single
cell PCR assays that CYSLTR1 receptor is expressed in most leukemic
and residual normal CD34þCD38 cells in BM of CML patients. We
also find the expression of the CYSLTR2 in most of these cells, with a
partially overlapping expression with CYSLTR1 receptor. CYSLTR1
mRNA has previously been shown to be expressed in normal he-
matopoietic CD34þ progenitors, and signaling via CYSLTR1 modu-
lated adhesion, proliferation and transmigration of the progenitors
in vitro [22,23], while the role of CYSLTR2 in hematopoiesis is so far
Fig. 3. Functional response of BM hematopoietic stem and progenitor cells from patients with CML and healthy donors to imatinib and leukotriene inhibitors in LTC-IC and
CFU-C assays.
(A-D) The growth response of CML (A, C) and normal BM (B, D) CD34þCD38 cells to imatinib (IM) zileuton (ZIL), montelukast (MON) and combination of IM with leukotriene
inhibitors in LTC-IC assay. The data are from 7 newly diagnosed CML patients and 5 normal BM donors.
(E) The growth response of CML CD34þ cells to IM, ZIL and MON in CFU-C colony assays. Data are the numbers of CFU-C per 150 CD34þ BM (circle) and PB (square) cells of 5
indicated CML patients. Each dot represents mean of duplicate measurements in the colony assays.
*p < 0.05 Wilcoxon matched-pairs signed rank test, compared to DMSO control. Horizontal bars show the median values.
Fig. 4. FISH analysis of BCR-ABL fusion gene expression in the cells derived from the LTC-IC assay shows the residual BCR-ABLþ cells after treatment with imatinib and
leukotriene inhibitors zileuton and montelukast.
The cells from individual LTC-IC culture wells were picked and transferred to microscopic slides by cytospin for the FISH analysis. (A) The representative images of the BCR-ABLþ
cells derived from the colonies in culture wells. (B) The frequencies of the BCR-ABLþ cells in wells after LTC-IC cultures from 4 patients. At least 55 cells in total in each sample were
counted for calculating the frequency of the BCR-ABLþ cells.
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By single cell PCR analysis we detected a very low overall fre-
quency of ALOX5 expression in the primitive BCR-ABLþ
CD34þCD38 LSC and BCR-ABL-CD34þCD38 nonleukemic cells of
CML patients, suggesting distinct regulation and functional
importance of 5-LO/ALOX5 in primitive human CML LSC and in the
mouse BCR-ABLþLSC. However, the expression of downstream
LTA4H in most leukemic and nonleukemic cells may indicate
transcellular biosynthesis of LT downstream of 5-LO in the LSC, as
reported in other cell types [24].
In the in vitro functional stem and progenitor cell assays of
primary CD34þCD38 cells of CML patients, imatinib significantly
inhibited the overall LTC-IC activity in leukemic, but not in normal
donor BM samples, supporting a specific inhibitory effect on BCR-
ABLþ LSC in these culture systems. Imatinib also significantly
inhibited CFU-C growth of the leukemic BM progenitors. In
contrast, zileuton, did not induce any significant overall inhibition
in the LTC-IC activity of CD34þCD38 cells or the CFU-C activity of
CD34þ cells of the CML patient BM samples. Our data suggest that
targeting the ALOX5 gene product, 5-LO using zileuton to treat CML
may not be as promising as expected from previously reported
mouse studies.
In contrast to the reported inhibition of the growth of CML blast
crisis cell lines by montelukast in a short term liquid culture assay
[11], we did not find significant overall growth suppression of BM
CD34þCD38 or CD34þ stem and progenitor cells of CML patients
by montelukast in LTC-IC or CFU-C assays, suggesting that phar-
macological inhibition of CYSLTR1 may not either be a promising
therapeutic strategy for eradicating CML LSC.
In summary, our findings indicate that the LT signaling pathway
via ALOX5 or CYSLTR1may be less important for survival of primary
human CML LSCs than that of mouse BCR-ABLþ cells or CML blast
cell lines. Consequently, inhibiting 5-LO or CYSLTR1 by zileuton and
montelukast may not be a promising option to eradicate CML LSC.
However, the expression and functional role of several other me-
diators of the LT pathway in human primitive hematopoietic stem
and progenitor cells and their leukemic counterparts in CML re-
mains elusive and should be assessed in further studies.
Conflict of interest
M.E., L.S., S.M., U.O.S. have participated as investigators in
several international clinical CML studies sponsored by pharma-
ceutical companies (Novartis, BMS, Pfizer and Ariad), generating
remuneration to these individuals or to their respective in-
stitutions/departments. Other authors declare no competing
financial interest regarding this study.
Acknowledgements
This study was supported by research funding from Swedish
Cancer Society (CAN 2012/891, CAN2015/652), Dr. Åke Olsson
Foundation, Swedish Research Council (2012e2070), The Cancer
Society in Stockholm and the King Gustaf V's Jubilee Foundation
(Radiumhemmets 131192 and 151241), The Swedish Childhood
Cancer Society (FoAss13/015, PROJ12/081) and Karolinska Institute
Wallenberg Institute for Regenerative Medicine to HQ and Swedish
Cancer Society (CAN 2010/590), Swedish Research Council (2008-
19616-59131-19), Medical Faculty, Lund University, Skåne Univer-
sity Hospital, Gunnar Nilsson Foundation, John Persson Foundation,
Gunnel Bj€ork Foundation and Georg Danielsson Foundation to ME,
and Finnish Cancer Institute, Finnish Cancer Societies and Signe and
Ane Gyllenberg Foundation to SM.
MD, AP, ME and HQ have participated in conception and design,
performing experiments, collection and assembly of data, dataanalysis and interpretation and manuscript writing. EG, WMW, JK
and ASJ performed experiments, collected data. PX, LS, SM, EYK and
UOS, contributed to data analysis and interpretation. All authors
have approved the final version of the manuscript.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.bbrc.2017.06.051.
Transparency document
Transparency document related to this article can be found
online at http://dx.doi.org/10.1016/j.bbrc.2017.06.051.
References
[1] M. Savona, M. Talpaz, Getting to the stem of chronic myeloid leukaemia, Nat.
Rev. Cancer 8 (2008) 341e350.
[2] H. Zhou, R. Xu, Leukemia stem cells: the root of chronic myeloid leukemia,
Protein Cell 6 (2015) 403e412.
[3] R. Bhatia, M. Holtz, N. Niu, R. Gray, D.S. Snyder, C.L. Sawyers, D.A. Arber,
M.L. Slovak, S.J. Forman, Persistence of malignant hematopoietic progenitors
in chronic myelogenous leukemia patients in complete cytogenetic remission
following imatinib mesylate treatment, Blood 101 (2003) 4701e4707.
[4] J.M. Poczobutt, T.T. Nguyen, D. Hanson, H. Li, T.R. Sippel, M.C. Weiser-Evans,
M. Gijon, R.C. Murphy, R.A. Nemenoff, Deletion of 5-lipoxygenase in the tumor
microenvironment promotes lung cancer progression and metastasis through
regulating T cell recruitment, J. Immunol. 196 (2016) 891e901.
[5] M. Peters-Golden, W.R. Henderson Jr., Leukotrienes, N. Engl. J. Med. 357
(2007) 1841e1854.
[6] Y. Chen, Y. Hu, H. Zhang, C. Peng, S. Li, Loss of the Alox5 gene impairs leukemia
stem cells and prevents chronic myeloid leukemia, Nat. Genet. 41 (2009)
783e792.
[7] T. O'Hare, M.S. Zabriskie, A.M. Eiring, M.W. Deininger, Pushing the limits of
targeted therapy in chronic myeloid leukaemia, Nat. Rev. Cancer 12 (2012)
513e526.
[8] C.M. Lucas, R.J. Harris, A. Giannoudis, E. McDonald, R.E. Clark, Low leukotriene
B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid
leukemia, Haematologica 99 (2014) 1710e1715.
[9] C. Roos, L. Stenke, L. Ohm, S. Widell, M. Kumlin, J.A. Lindgren, S. Tornhamre,
Clinical imatinib mesylate treatment induces early normalisation of aberrant
neutrophil leukotriene C4 synthase expression and activity in chronic myeloid
leukaemia, Br. J. Haematol. 142 (2008) 992e995.
[10] M. Sjolinder, L. Stenke, B. Nasman-Glaser, S. Widell, J. Doucet, P.J. Jakobsson,
J.A. Lindgren, Aberrant expression of active leukotriene C(4) synthase in
CD16(þ) neutrophils from patients with chronic myeloid leukemia, Blood 95
(2000) 1456e1464.
[11] E. Yektaei-Karin, A. Zovko, A. Nilsson, B. Nasman-Glaser, L. Kanter,
O. Radmark, J. Wallvik, M. Ekblom, M. Dolinska, H. Qian, L. Stenke, Modulation
of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia,
Leuk. Lymphoma (2016) 1e11.
[12] M. Baccarani, M.W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J.F. Apperley,
F. Cervantes, R.E. Clark, J.E. Cortes, F. Guilhot, H. Hjorth-Hansen, T.P. Hughes,
H.M. Kantarjian, D.W. Kim, R.A. Larson, J.H. Lipton, F.X. Mahon, G. Martinelli,
J. Mayer, M.C. Muller, D. Niederwieser, F. Pane, J.P. Radich, P. Rousselot,
G. Saglio, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, J.L. Steegmann,
J.M. Goldman, R. Hehlmann, European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013, Blood 122 (2013) 872e884.
[13] D.E. Hogge, P.M. Lansdorp, D. Reid, B. Gerhard, C.J. Eaves, Enhanced detection,
maintenance, and differentiation of primitive human hematopoietic cells in
cultures containing murine fibroblasts engineered to produce human steel
factor, interleukin-3, and granulocyte colony-stimulating factor, Blood 88
(1996) 3765e3773.
[14] W.M. Wong, M. Dolinska, M. Sigvardsson, M. Ekblom, H. Qian, A novel Lin-
CD34þCD38- integrin alpha2- bipotential megakaryocyte-erythrocyte pro-
genitor population in the human bone marrow, Leukemia 30 (2016)
1399e1402.
[15] H. Qian, A. Badaloni, F. Chiara, J. Stjernberg, N. Polisetti, K. Nihlberg,
G.G. Consalez, M. Sigvardsson, Molecular characterization of prospectively
isolated multipotent mesenchymal progenitors provides new insight into the
cellular identity of mesenchymal stem cells in mouse bone marrow, Mol. Cell.
Biol. 33 (2013) 661e677.
[17] Y. Zhao, A. Delaney, A. Raouf, K. Raghuram, H.I. Li, A. Schnerch, X. Jiang,
A.C. Eaves, A.A. Marra, C.J. Eaves, Differentially expressed and novel tran-
scripts in highly purified chronic phase CML stem cells, Blood 112 (2008) 193.
ASH abstract.
[18] X. Jiang, Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, C. Eaves, Chronic
myeloid leukemia stem cells possess multiple unique features of resistance to
BCR-ABL targeted therapies, Leukemia 21 (2007) 926e935.
M. Dolinska et al. / Biochemical and Biophysical Research Communications 490 (2017) 378e384384[19] L. Burke, C.T. Butler, A. Murphy, B. Moran, W.M. Gallagher, J. O'Sullivan,
B.N. Kennedy, Evaluation of cysteinyl leukotriene signaling as a therapeutic
target for colorectal cancer, Front. Cell Dev. Biol. 4 (2016) 103.
[20] M. Xiao, H. Ai, T. Li, P. Rajoria, P. Shahu, X. Li, Targeting of the BLT2 in chronic
myeloid leukemia inhibits leukemia stem/progenitor cell function, Biochem.
Biophys. Res. Commun. 472 (2016) 610e616.
[21] A.C. Drost, G. Seitz, A. Boehmler, M. Funk, K.P. Norz, A. Zipfel, X. Xue, L. Kanz,
R. Mohle, The G protein-coupled receptor CysLT1 mediates chemokine-like
effects and prolongs survival in chronic lymphocytic leukemia, Leuk. Lym-
phoma 53 (2012) 665e673.
[22] F. Bautz, C. Denzlinger, L. Kanz, R. Mohle, Chemotaxis and transendothelialmigration of CD34(þ) hematopoietic progenitor cells induced by the inflam-
matory mediator leukotriene D4 are mediated by the 7-transmembrane re-
ceptor CysLT1, Blood 97 (2001) 3433e3440.
[23] A.M. Boehmler, A. Drost, L. Jaggy, G. Seitz, T. Wiesner, C. Denzlinger, L. Kanz,
R. Mohle, The CysLT1 ligand leukotriene D4 supports alpha4beta1- and
alpha5beta1-mediated adhesion and proliferation of CD34þ hematopoietic
progenitor cells, J. Immunol. 182 (2009) 6789e6798.
[24] S. Zarini, M.A. Gijon, A.E. Ransome, R.C. Murphy, A. Sala, Transcellular
biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal
inflammation, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 8296e8301.
